Foresight Diagnostics
Business Services · Colorado, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
12705 E Montview Blvd Ste 360, Aurora, C...Website
www.foresight-dx.comRevenue
$6.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
1
2
1
1
About Foresight Diagnostics
Foresight Diagnostics is a privately-held cancer diagnostics company. The company has developed a novel liquid biopsy testing platform for the measurement of minimal residual disease (MRD) that is broadly applicable to a variety of cancers and that is significantly more sensitive than existing tests (with a detection limit below 0.0001% or one part-per-million). This improved sensitivity provides actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients.Explore more
Foresight Diagnostics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Foresight Diagnostics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if Foresight Diagnostics had a recent Job posting/layoffs
Product Launch: Get notified when Foresight Diagnostics launches new products
Check if Foresight Diagnostics has recently received funding, and reach out quickly before it becomes old news!
Foresight Diagnostics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Foresight Diagnostics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Foresight Diagnostics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Foresight Diagnostics recently announced quarterly report
Check out if Foresight Diagnostics is spiking on competitors!
Recommended Actions
Find VP level buyers at Foresight Diagnostics
Find more new buyers
Compare Similar Companies to Foresight Diagnostics
Compare insights from companies similar to Foresight Diagnostics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Foresight Diagnostics
$6.8M
51-200
Private
$104.3M
2020
RG
Ruben GutierrezSenior Vice President and General Counsel
Company Profile Activity
Activity Insights
Foresight Diagnostics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Foresight Diagnostics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Foresight Diagnostics.
Foresight Diagnostics financials insights
Gather financial insights about Foresight Diagnostics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$12.5M
2023
Series B
$58.8M
2024
Series B
$33M
Foresight Diagnostics Tech Stack
A closer look at the technologies used by Foresight Diagnostics
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Open Position
Foresight Diagnostics News & Media
Foresight Diagnostics Announces Multiple Presentations in Lymphoma Featuring PhasED-Seq™ Ultrasensitive MRD Analysis at the upcoming ASH Annual Meeting
BOULDER, Colo., Dec. 3, 2025 /PRNewswire/ -- Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection technology, today announced the presentation of multiple lymphoma studies featuring Foresight CLARITY™ (PhasED-Seq) minimal residual disease (MRD)...Foresight Diagnostics to Present Clinical Performance Data on Foresight CLARITY™ MRD at IASLC 2025 World Conference on Lung Cancer
BOULDER, Colo., Sept. 5, 2025 /PRNewswire/ -- Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection, today announced an oral presentation in partnership with University Health Network's (UHN) Princess Margaret Cancer Centre at the IASLC 2025 World...Foresight Diagnostics and Roche Enter Licensing Agreement for PhasED-Seq™ Technology in Non-Hodgkin's Lymphoma
The Agreement Closes the Litigation Between the Parties BOULDER, Colo., Aug. 29, 2025 /PRNewswire/ -- Foresight Diagnostics ("Foresight") today announced that it has entered into a limited licensing agreement with Roche Molecular Systems and Roche Sequencing Systems (together, "Roche")...Foresight Diagnostics Announces Publication of Landmark Study Demonstrating Prognostic Value of Ultrasensitive ctDNA-MRD Detection in Large B-Cell Lymphoma
BOULDER, Colo., Aug. 18, 2025 /PRNewswire/ -- Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection, today announced the publication of a landmark pooled analysis in the Journal of Clinical Oncology demonstrating that MRD analysis using Foresight...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Foresight Diagnostics
Sign Up For FreeTo access detailed company insights
Foresight Diagnostics is a privately-held cancer diagnostics company. The company has developed a novel liquid biopsy testing platform for the measurement of minimal residual disease (MRD) that is broadly applicable to a variety of cancers and that is significantly more sensitive than existing tests (with a detection limit below 0.0001% or one part... Read More
